Inactive Instrument

Analyst Reco. Novozymes A/S Other OTC

Equities

NOVONESIS : Key segments outperform in average Q1 24 showing	10/05
NOVOZYMES : Q4 23: destocking noise offsets recovery in other key segments	08/02
NOVOZYMES : Q3 23: Stable volume growth underpinned by a recovery in key segments	09/11
NOVOZYMES : Q2 23: Broad-based weakness leads to a guidance downgrade	10/23/10
Berenberg Innovation Conference	06/23/06	FA
NOVOZYMES : BioEnergy surprise drives Q1 23 momentum	05/23/05
NOVOZYMES : EPS cut (2022: +2.3%, 2023: -14.3%)	28/23/28
NOVOZYMES : Q4 22: solid top-line momentum even as profits fall short	30/23/30
NOVOZYMES : Novozymes/Chr. Hansen: Pricey ‘growth’ punt?	16/22/16
European shares slip on fears over rising China COVID cases, await rate decisions	12/22/12	RE
Berenberg European Conference	05/22/05	FA
Roche’s Alzheimer’s failure has sector-wide implications	14/22/14
NOVOZYMES : Q3 22: Not as rosy as it looks	14/22/14
NOVOZYMES : Solid Q2; FY 22 top-line guidance looks conservative	22/22/22
BNPP Exane European CEO Conference	15/22/15	FA
Berenberg USA Conference	25/22/25	FA
NOVOZYMES : Ex-household care, strong start to FY 22	28/22/28
NOVOZYMES : Q4 21: household weakness and inflation in focus	03/22/03
Berenberg European Conference	06/21/06	FA
NOVOZYMES : Strong Q3 21; Household care ‘only’ sore spot	29/21/29

No results for this search

NOVONESIS : Key segments outperform in average Q1 24 showing

May 10, 2024 at 10:02 pm IST